Common questions about Dexilant (FAQ)
Q: What is the main difference between Dexilant and other PPIs like omeprazole or pantoprazole?
A: Official documents indicate that Dexilant contains the active ingredient dexlansoprazole, which is the R-enantiomer of lansoprazole. A key distinction from many other medicines in this class is its dual delayed-release formulation. This design is engineered to release the medicine in two distinct phases, aiming for a sustained duration of acid suppression.
Q: Are there any long-term health concerns associated with using Dexilant?
A: Regulatory warnings associated with the PPI class for long-term use, typically defined as one year or longer, mention a potential risk of bone fractures, especially of the hip, wrist, or spine. Other risks noted in official information include low serum magnesium (Hypomagnesemia) and the possible development of Fundic Gland Polyps. Use for longer than three years may also be associated with Vitamin B12 deficiency.
Q: Is it safe to take Dexilant with over-the-counter pain relievers like ibuprofen?
A: Official documents describe no specific drug-to-drug interaction between dexlansoprazole and non-steroidal anti-inflammatory drugs ( NSAIDs) like ibuprofen. Discussing the combination of any medicine with a healthcare provider is generally recommended.
Q: What are the documented effects of Dexilant on bone health?
A: Official regulatory documents report that therapy with the PPI class, particularly at high doses and for long periods (one year or longer), may be associated with an increased risk of osteoporosis-related fractures. These fractures have been reported in the hip, wrist, or spine.
Q: Is Dexilant associated with low magnesium levels?
A: Yes, official regulatory information notes that Hypomagnesemia, or low serum magnesium, has been rarely reported in patients treated with PPIs. This condition is typically observed after at least one year of therapy. The risk is noted to be greater in patients who are also taking other medicines that have been known to cause low magnesium.
Q: What are the known potential interactions between Dexilant and blood thinners?
A: Official information describes an interaction with Warfarin that requires close monitoring of blood coagulation time. Regarding Clopidogrel, regulatory documents state that no dose adjustment is specified when co-administering it with an approved dose of Dexilant.
Q: What is the general duration of treatment with Dexilant for most people?
A: The recommended length of treatment depends on the specific condition being addressed. Official guidelines specify up to 8 weeks for the initial healing phase of erosive esophagitis ( EE). The treatment for maintaining EE healing is up to 6 months in adults, and the treatment for symptomatic non-erosive GERD is typically 4 weeks.
Q: Can Dexilant be taken with antacids if needed?
A: There is no contraindication against taking Dexilant with antacids listed in official regulatory documents. The reduction in stomach acid caused by both Dexilant and antacids may affect how certain other medicines are absorbed.
Q: Is Dexilant effective for both daytime and nighttime heartburn symptoms?
A: The specialized dual delayed-release formulation is designed to provide sustained suppression of gastric acid. This formulation aims for consistent acid control over a 24-hour period, which covers both daytime and nighttime periods.
Q: Does Dexilant start working right away, or does it take a few days?
A: The medicine is generally used as a treatment course over time. Clinical studies for symptomatic non-erosive GERD evaluated effectiveness based on symptom changes observed over a four-week period. The recommended full duration of therapy for this indication is typically four weeks.
Q: Can Dexilant affect blood test results?
A: Official documents describe that Dexilant can interfere with certain diagnostic tests. This includes tests used to detect neuroendocrine tumors, such as the Chromogranin A ( CgA) test, and it may also affect the results of the secretin stimulation test for gastrinoma.
Q: Does Dexilant cause weight gain or weight loss?
A: Neither weight gain nor weight loss are listed as common side effects of Dexilant. However, 'unusual weight gain' has been noted in postmarketing reports in association with monitoring for a rare, serious side effect ( Acute Tubulointerstitial Nephritis), but the frequency is not known.
Q: What are the signs that Dexilant may not be working for a person?
A: Official guidance states that if a person experiences a suboptimal response to therapy or an early symptomatic relapse after completing treatment, additional follow-up or diagnostic testing may be considered by a healthcare provider. These situations are described in official guidance as conditions that may warrant follow-up.
Q: Does taking Dexilant affect the absorption of vitamins or nutrients?
A: Long-term daily use of the PPI class, for example, longer than three years, may be associated with malabsorption or a deficiency of Vitamin B12. The reduction in stomach acid caused by the medicine can also affect the absorption of certain minerals and other medicines, such as iron salts.
Q: Are there any food or drink restrictions while taking Dexilant?
A: Official product information states that Dexilant can be taken without regard to food. No specific food or drink restrictions are listed in the regulatory label.
Q: Can Dexilant cause headaches, and if so, how common is this side effect?
A: Yes, headache is a documented adverse reaction. Official labeling classifies headache as a Common side effect, meaning it is reported in up to 1 in 10 patients.
Q: Can Dexilant cause sleeping difficulties or changes in mood?
A: Insomnia, which is difficulty sleeping, is listed as an Uncommon adverse reaction in the official product information, meaning it affects up to 1 in 100 patients. Mood or mental changes have also been noted in postmarketing reports, but the frequency is not known.
Q: Is Dexilant safe for someone with known kidney issues?
A: Regulatory guidance states that dose adjustment is generally not necessary for patients with renal impairment. However, it is also noted that PPI therapy, including Dexilant, is associated with a rare potential for Acute Interstitial Nephritis ( AIN), which is a serious kidney condition.
Q: Can Dexilant be used to prevent acid reflux, or is it only for treatment?
A: Dexilant is indicated by the FDA for the healing of erosive esophagitis ( EE), the maintenance of healed EE, and the treatment of heartburn associated with symptomatic non-erosive GERD. These indications focus on the management and treatment of acid-related conditions.
Q: Do studies exist that examine the use of Dexilant in children?
A: Yes, the safety and effectiveness of Dexilant have been studied and established for use in pediatric patients 12 years of age and older. Regulatory information notes that use is not recommended in children younger than 12 years of age.
Q: Does Dexilant interact with any herbal supplements?
A: Yes, official documents explicitly advise to avoid taking Dexilant with St. John’s Wort. This herbal supplement is described as a strong enzyme inducer, which can decrease the exposure of dexlansoprazole in the body.
Q: Is it described that Dexilant causes changes in bowel habits?
A: Yes, the most common gastrointestinal adverse effect reported in clinical trials is diarrhea. Constipation has also been noted in postmarketing reports, but the frequency is not known.
Q: Does Dexilant have a specific safety profile regarding liver function?
A: Official guidance outlines dosage adjustments for patients with moderate hepatic impairment (Child-Pugh Class B). Use is advised against in cases of severe hepatic impairment (Child-Pugh Class C). Drug-induced hepatitis has also been noted in postmarketing reports.
Q: Is there a maximum time length that Dexilant is typically studied for in clinical trials?
A: Clinical studies for the maintenance of healed erosive esophagitis in adults did not extend beyond six months. For adolescents, controlled studies for this same indication did not extend beyond 16 weeks.
Q: Can Dexilant cause dizziness, and if so, how common is this side effect?
A: Yes, dizziness is a documented adverse reaction. Official labeling classifies dizziness as an Uncommon side effect, meaning it is reported in up to 1 in 100 patients.
Q: What are some of the less common but important side effects of Dexilant to be aware of?
A: Official documents highlight several serious or less common reactions associated with the PPI class. These include Clostridium difficile-associated diarrhea ( CDAD), Acute Interstitial Nephritis ( AIN), and the potential for bone fractures and Hypomagnesemia (low serum magnesium) with long-term use.
Q: How is Dexilant elimination described in regulatory sources?
A: Regulatory sources describe dexlansoprazole as being extensively metabolized, or processed, by the liver, primarily involving the CYP2C19 and CYP3A4 enzyme systems. The inactive breakdown products are then excreted through both urine and feces.
Q: What is the role of Dexilant in treating different types of erosive esophagitis?
A: Dexilant is indicated for the healing of all grades of erosive esophagitis ( EE), which is a condition where the lining of the esophagus is damaged by stomach acid.
Q: Does Dexilant affect how the body metabolizes other drugs?
A: Yes, official product information indicates that Dexilant can influence the way the body processes other medicines. This primarily occurs through the interaction with certain liver enzymes, which may alter the concentration levels of some co-administered drugs.
Q: What is the purpose of the different strengths of Dexilant capsules?
A: Official dosing guidelines use the two different strengths to match the clinical need. The 60 mg strength is specified for the initial healing phase of erosive esophagitis ( EE), while the 30 mg strength is typically specified for the maintenance of healing and for symptomatic non-erosive GERD.
Q: Can taking Dexilant increase the risk of developing certain infections?
A: Yes, official warnings note that therapy with the PPI class may be associated with an increased risk of Clostridium difficile-associated diarrhea ( CDAD). This is an infection that can occur in the intestine.
Q: How does the 'delayed-release' part of the drug relate to its effectiveness?
A: As an acid-sensitive compound, dexlansoprazole uses a delayed-release mechanism to protect the drug from being prematurely broken down by stomach acid. This allows it to be absorbed later in the small intestine, enabling it to reach the parietal cells for its intended acid-suppressing effect.
